Home >> Marketplace Directory >> Assay for routine screening of CFTR gene, 7/17

Assay for routine screening of CFTR gene, 7/17

image_pdfCreate PDF

 

July 2017—Swift Biosciences has commercially released its Accel-Amplicon CFTR Panel, which aims to provide research laboratories with a more comprehensive, next-generation sequencing–based approach to interrogate the coding region and select introns within the cystic fibrosis transmembrane conductance regulator gene for disease-relevant mutations and variants. The panel is designed to offer a higher resolution view into the CFTR gene and produces ready-to-sequence libraries in two hours.

The Accel-Amplicon CFTR panel covers all 27 exons, including the 5’ and 3’ untranslated regions, and regions of interest in introns 1, 12, 22, and 25, and captures all recommended ACMG common CFTR mutations. The panel generates targeted libraries compatible with Illumina sequencing platforms and comes as a complete kit with all components necessary for generating ready-to-sequence libraries, including primer pairs and indexed sequencing adapters.

Swift Biosciences, 734-330-2568

CAP TODAY
X